PAK-SEHAT flags hidden cardiac risks in symptom-free Pakistanis
Islamabad: Preliminary findings from Pakistan’s first comprehensive heart study have revealed a heavy burden of cardiac risk factors among adults who had no symptoms of disease, leading cardiologists said on Saturday.
The baseline results of the Pakistan Study of Premature Coronary Atherosclerosis in Young Adults (PAK-SEHAT) were presented during the primary prevention session of the 55th CardioCon at the Serena Hotel in Islamabad.
According to the study of 2,000 apparently healthy adults, 78 percent of participants were obese, 33 percent had hypertension and 22 percent were diabetic. Another 23 percent were found to be prediabetic.
Dr Bashir Hanif, the principal investigator, said obesity was assessed under the Asian body mass index cut-off of 25. It was found in 81 percent of women and 74 percent of men. He said 68 percent of participants had low levels of “good” HDL cholesterol, while 32 percent reported a family history of premature coronary heart disease.
Dr Hanif said the study also found calcium in the coronary arteries of 26 percent of participants, suggesting that conventional clinical risk assessment could underestimate the disease actually present in apparently healthy people.
He said the risk factors were not appearing separately. Hypertension, dyslipidaemia, obesity and diabetes were coexisting in the same individuals, and a higher number of such factors was linked with substantially more silent atherosclerosis.
PAK-SEHAT is a prospective cohort study being conducted jointly by the Fatima Hanif Foundation and Getz Pharma, which supported the initiative through an unrestricted research grant. It has been described as the first study of its kind in the country and dubbed a “mini Framingham” of Pakistan after the landmark United States heart study.
Dr Hanif said the participants included men aged 35 to 60 and women aged 35 to 65, recruited from all four provinces and Islamabad through eight centres. None had symptomatic cardiovascular disease. Their mean age was 39 years.
He said the baseline assessment included blood tests, carotid ultrasound and coronary CT angiography, while the participants would be followed for five years.
Dr Khurram Nasir, co-principal investigator and chief of the Division of Cardiovascular Prevention and Wellness at Houston Methodist, said PAK-SEHAT would become a “gold mine” of data for Pakistan.
He said South Asians, particularly Pakistanis, had remained largely “invisible” in global research, leaving major gaps in understanding the causes, early onset and risk factors of heart disease in them.
Dr Nasir, who is also editor-in-chief of the American Journal of Preventive Cardiology, said the results suggested that being a man aged 35 or above was itself a risk factor for Pakistanis, possibly because of sedentary lifestyles, genetics and environmental factors. He said details would be clearer once the study was finalised.
He said heart disease appeared to begin 10 to 15 years earlier among Pakistanis than in other populations, but the reasons behind early heart attacks and deaths in younger people and men had not been properly investigated.
PAK-SEHAT, he said, would help explain why the disease started early and how it could be prevented. He also paid tribute to Dr Hanif and Getz Pharma for making the landmark study possible.
Kashif Amin, Head of Public Health at Getz Pharma, said cardiovascular disease was taking lives silently in Pakistan, while guidelines and risk-scoring models had relied on Western data. He said prevention must begin with Pakistan’s own data.
He said Getz Pharma’s vision went beyond medicines and aimed to shift focus from late-stage treatment to primary prevention, with PAK-SEHAT, a multicentric prospective study, at the centre of that approach.
By uncovering subclinical atherosclerosis and mapping how hypertension, diabetes, dyslipidaemia and lifestyle factors interact, he described the study as a national blueprint for protecting Pakistan’s youth, workforce and families. He said Getz Pharma would continue connecting clinicians, investigators and the population.



